Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Abstract excerpt

To the editor: Recent reports on the genetic landscape of the plasma cell malignancy, multiple myeloma (MM), have revealed potential therapeutic targets such as activating mutations in BRAF kinase in subsets of patients.[1][1][⇓][2][⇓][3]-[4][4] However, assuming suitable targeted therapies

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors